These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 6313954)

  • 1. Interaction of catecholamine-derived alkaloids with central neurotransmitter receptors.
    Nimit Y; Schulze I; Cashaw JL; Ruchirawat S; Davis VE
    J Neurosci Res; 1983; 10(2):175-89. PubMed ID: 6313954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigations on the binding properties of the nootropic agent pyroglutamic acid.
    Barone D; Spignoli G
    Drugs Exp Clin Res; 1990; 16(2):85-99. PubMed ID: 1976055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electroconvulsive shock and neurotransmitter receptors: implications for mechanism of action and adverse effects of electroconvulsive therapy.
    Lerer B
    Biol Psychiatry; 1984 Mar; 19(3):361-83. PubMed ID: 6144329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors in vitro and in vivo.
    Martin GE; Williams M; Pettibone DJ; Zrada MM; Lotti VJ; Taylor DA; Jones JH
    J Pharmacol Exp Ther; 1985 May; 233(2):395-401. PubMed ID: 2987478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amitriptylinoxide: receptor-binding profile compared with other antidepressant drugs.
    Borbe HO; Zierenberg O
    Pharmacopsychiatry; 1985 Sep; 18(5):314-9. PubMed ID: 2996040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergic receptors.
    Bylund DB
    J Pharmacol Exp Ther; 1981 Apr; 217(1):81-6. PubMed ID: 6110776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor binding profile of tibalosine, a new antihypertensive.
    Chatelain P; Friedhoff AJ; Meller E; Mennini T; Gorissen H; Roba J
    Arzneimittelforschung; 1984; 34(7):754-8. PubMed ID: 6093823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of catecholamine-derived alkaloids and beta-adrenergic blocking agents on stereospecific binding of 3H-naloxone.
    Tampier L; Alpers HS; Davis VE
    Res Commun Chem Pathol Pharmacol; 1977 Aug; 17(4):731-4. PubMed ID: 19827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain neurotransmitter receptor alterations in offspring of rats exposed to phenobarbital, phenytoin or their combination during pregnancy.
    Seth PK; Alleva FR; Takagi S; Yen-Koo HC; Balazs T
    Neurotoxicology; 1987; 8(1):45-53. PubMed ID: 3031564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotransmitter-receptor binding in various brain regions in ethanol-dependent rats.
    Hunt WA; Dalton TK
    Pharmacol Biochem Behav; 1981 May; 14(5):733-9. PubMed ID: 6113608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain.
    Rosenfeld MR; Makman MH
    J Pharmacol Exp Ther; 1981 Mar; 216(3):526-31. PubMed ID: 7205633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of salsolinol and its mono-O-methylated analogs with adrenergic and dopaminergic receptors in the rabbit ear artery.
    Nelson SH; Steinsland OS
    J Pharmacol Exp Ther; 1983 Jan; 224(1):193-8. PubMed ID: 6294277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of non-steroidal antiestrogens with dopamine receptor binding.
    Hiemke C; Ghraf R
    J Steroid Biochem; 1984 Dec; 21(6):663-7. PubMed ID: 6098784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects.
    Ison PJ; Peroutka SJ
    Cancer Treat Rep; 1986 May; 70(5):637-41. PubMed ID: 3011258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of the anticholinesterase activity of a series of organophosphates with their ability to compete with agonist binding to muscarinic receptors.
    Ward TR; Ferris DJ; Tilson HA; Mundy WR
    Toxicol Appl Pharmacol; 1993 Oct; 122(2):300-7. PubMed ID: 8212012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No circadian rhythms of serotoninergic, alpha-, beta-adrenergic and imipramine binding sites in rat brain regions.
    Di Lauro A; Giannini CP; Muscettola G; Greco AM; de Franciscis P
    Chronobiol Int; 1986; 3(2):123-6. PubMed ID: 2824069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of neurotransmitter receptor binding by ergot derivatives.
    Hruska RE; Silbergeld EK
    J Neurosci Res; 1981; 6(1):1-11. PubMed ID: 6111611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding.
    Peroutka SJ; Snyder SH
    Science; 1980 Oct; 210(4465):88-90. PubMed ID: 6251550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
    Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
    Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of muscarinic cholinergic receptor affinity for antagonists in rat heart.
    Martin MW; Smith MM; Harden TK
    J Pharmacol Exp Ther; 1984 Aug; 230(2):424-30. PubMed ID: 6379149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.